



UNIVERSITY OF OTTAWA
HEART INSTITUTE
INSTITUT DE CARDIOLOGIE
DE L'UNIVERSITÉ D'OTTAWA

RESEARCH



CNS Effects of Aldosterone : *Critical Roles in salt-sensitive hypertension and CHF.*


Frans HH Leenen

MD, PhD, FRCPC, FAHA

Renin–Angiotensin – Aldosterone System

➤ Circulatory RAAS

- ## ➤ Tissue RAAS:
- arteries, heart
 - kidneys
 - brain




Aldosterone, Ang II and the CNS

- **Source:** circulation or locally produced?
- **Function:** irrespective of source


Salt – Sensitive hypertension : circulatory RAAS ↓
brain RAAS ↑

CHF post MI : circulatory & cardiac RAAS ↑
brain RAAS ↑




Salt and Circulatory RAAS in Dahl R and S rats.

Plasma Aldosterone




Plasma Ang II




■ Reg Salt
■ High Salt for 4 weeks

Salt and tissue RAAS in Dahl S

Angiotensin II



Aldosterone




■ Control
■ 8% for 3 wks


(Bayorh et al. Clin Exper Hypertens 2005)

Salt and hypothalamic aldosterone and corticosterone in Dahl S

Aldosterone





Corticosterone



■ RNa
■ HNa

* $p < 0.05$ vs RNa

CSF [Na⁺] & MAP on high salt in Dahl S versus R




* p < 0.05 vs RNa


(Huang et al. Am J Physiol 2004)

CSF $[Na^+]$ \uparrow and hypothalamic aldosterone and corticosterone

Aldosterone




Corticosterone



■ Icv aCSF
■ Icv Na⁺ rich aCSF for 2 weeks

* p<0.05 vs others

Enhanced BP ↑ to CSF [Na⁺] in Dahl S vs R



* p < 0.05 vs other a: p < 0.05 vs aCSF

(Huang et al. Am J Physiol 2001)

Activation of neural mechanisms by high salt in Dahl S

- Genetic dysregulation of CNS Na⁺-homeostasis :

Enhanced Na⁺ - transport from blood into CSF



CNS aldosterone ↑




Neuronal activation ↑



Sympathetic activity ↑



Hypertension



Functional role of aldosterone in the CNS


➤ Central MR Blockade

Limitations: not specific for aldosterone
not specific for locally produced steroid


➤ Aldosterone synthase inhibition

➤ 1 vs 2 → MR activation due to locally produced aldosterone.

Aldosterone synthase inhibitor



**(+)-(5R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)
benzonitrile hydrochloride**




FAD 286 is a single (+) -enantiomer

(Fiebeler et al. Circulation 2005)


CSF $[Na^+]$ \uparrow and hypothalamic aldosterone and corticosterone

Central aldosterone synthase inhibition

Aldosterone



Corticosterone






* $p < 0.05$ vs others

100 $\mu\text{g}/\text{kg}/\text{day}$


CSF [Na⁺] and sympathetic activity

Central aldosterone synthase inhibition

Air Stress



Baroreflex control of RSNA




* p<0.05, vs aCSF with/without AS inh; a: p<0.05, vs Na⁺-rich aCSF+veh

* p<0.05, vs others


Dahl S on HNa for 4 weeks

Central aldosterone synthase inhibition

Aldosterone



Corticosterone




■ RNA
■ HNa

80 µg/kg/day


BP and HR in Dahl S on high salt

Central aldosterone synthase inhibitor vs MR blocker

Resting MAP



Resting HR



* $p < 0.05$ vs others
b: vs RNA+aCSF

■ RNA
■ HNa

CONCLUSION

- **Central blockade of aldosterone synthesis or MR prevents to a large extent the salt-induced hypertension in Dahl S.**

➔ *locally in the CNS produced aldosterone via MR plays a major role*

New Paradigm:

- **High salt diet via CSF $[Na^+]$ ↑ activates aldosterone – MR and sodium transport in the CNS.**

Shift in Paradigm from Kidney to CNS

Old Paradigm:

- Intrinsic changes in renal function lead to a defect in the kidneys' ability to excrete salt and to an increase in BP until sodium balance is restored.

"the Guyton Dogma"

New Paradigm:

- Kidneys of genetic models of salt – induced hypertension do not require hypertension, and the animals live happy (*happier ?*) without.
- Kidneys are a "sensor and /or effector" organ like the arteries and the heart, and in general the CNS determines the set – point of BP.

Changing Face of CHF

Past and Present

Hypertension → LVH → LV dysfunction → CHF

Present and Future

Hypertension

Dyslipidemia → Atherosclerosis → MI → LV remodeling/dysfunction


Diabetes

Smoking



CHF

CHF mortality still very high



(Davis et al. Circulation, 2006)

LV remodeling following MI


**Acute Infarction,
hours**



**Infarct Expansion,
hours to days**



**Global Remodeling,
days to months**



Stimuli for cardiac remodeling post MI

Cardio-centric view: diastolic wall stress ↑
systolic wall stress ↑


→ progressive LV dilation and hypertrophy

Cardio-renal view: reduced cardiac output and renal perfusion

→ activation of circulatory RAAS

salt and water retention

Neuro-hormonal view: sympathetic hyperactivity
circulatory, cardiac, renal RAAS ↑
vasopressin ↑
pro-inflammatory cytokines ↑



CNS and CHF Post MI

**Brain RAAS: locally produced aldosterone
→ MR & AT₁-rec stimulation**


➤ **sympathetic activity**

& other peripheral mechanisms ↑

➤ **cardiac remodeling / dysfunction post MI**



Myocardial Infarction



Transgenic Rats

To assess the role of Angiotensins locally produced in the brain

Glial fibrillary acidic protein promoter

Angiotensinogen Antisense DNA

Angiotensinogen antisense RNA (glia only)

Angiotensinogen mRNA



Angiotensinogen

SD TG Rats

Hypothalamic Angiotensinogen, pmol/mg protein

1.5 0.1

Plasma Angiotensinogen, nmol/ml

1.4 1.4


(Schinke et al. PNAS, 1999)

CNS aldosterone post MI


Central aldosterone synthase inhibitor

Hypothalamus

2 weeks




4 weeks



Hippocampus


4 weeks




* $p \leq 0.05$

Sympathetic Hyperactivity in CHF post MI


- **set point** ↑
- **reactivity** ↑
- **baroreflex-control** ↓



Blockade of Brain MR-AT₁-rec prevents sympathetic hyperactivity post MI




(Francis et al. AJP, 2003)



(Huang et al. AJP, 2005)


Blockade of brain RAAS prevents plasma Ang II and aldosterone \uparrow post MI

Sham
MI



(Wang et al. Circ Res, 2004)


Sham
MI
MI & ICV Spironolactone




(Lal et al. Card vasc Res, 2004)

Blockade of brain RAAS prevents LV aldosterone ↑ post MI

TG rats




Wistar rats with icv
spironolactone



(Lal et al. JMCC, 2005)

* $p < 0.05$ vs other

Blockade of brain MR prevents plasma TNF- α \uparrow post MI



* p<0.05, vs other

(Francis et al, AJP, 2004)

CNS and CHF Post MI

Brain RAAS: locally produced aldosterone

→ MR & AT₁-rec stimulation

➤ **sympathetic activity**

& other peripheral mechanisms ↑

➤ **cardiac remodeling / dysfunction post MI**



Parameters of LV remodeling

- **LV diameter**
- **cardiomyocyte numbers and size**
- **extracellular matrix - collagen**

Parameters of LV dysfunction and CHF


- **LVEDP, LVPSP, LV dP/dt max**
- **lung weight**
- **RV weight and diameter**

LV dimensions at 4 weeks post MI


Central Blockades

- Sham
- MI icv veh
- MI icv AS inh


Diastolic






Systolic



EF (%)




(mm)



- Sham
- MI icv veh
- MI icv los
- MI icv spir

* p<0.05 vs sham; ^ap<0.05 vs MI +veh

LV pressure-volume curves in transgenic vs. SD rats at 8 wks post MI



* P<0.05 vs sham; # P<0.05 vs SD MI




MI size : 40 ± 3 for TG and 40 ± 4 for SD

(Wang et al. Circ Res, 2004)


Interstitial Fibrosis in Peri-infarct Zone

Effect of central MR blocker


Interstitial fibrosis (magnification X400)




Fibrillar collagen by SEM (magnification X8000)



Sham






MI



MI + Icv Spironolactone
(Lal et al. Card vasc Res, 2004)

Oral vs icv spironolactone and MI-Induced changes in hemodynamics




■ Sham
■ MI + Vehicle
■ MI + Spironolactone

* $p < 0.05$ vs sham; a $p < 0.05$ vs MI+Vehicle

(Lal et al. Card vasc Res, 2004)

LV function at 4 weeks post MI

icv losartan versus icv spironolactone




* p < 0.05 vs sham; ^ap < 0.05 vs MI + veh

(Huang et al. JMCC 2007)


LV function 4 weeks post MI

Central aldosterone synthase inh



* p<0.05 vs sham; ^ap<0.05 vs MI +veh




CNS and LV dysfunction post MI



Sympathetic activity post MI

Effects of systemic losartan

Air Stress




(Huang et al. JMCC, 2007)

Losartan and sympathetic activity in patients with CHF

MSNA

Plasma Norepinephrine




p<0.05 vs baseline

+ p< 0.05 compared to losartan 50 mg/day

(Ruzicka et al. ESC, 2007)

The Brain: The forgotten target in Heart Failure



(Leenen. Circ Res, 2007)